Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AEterna Zentaris subsidiary acquires Multichem
This acquisition was financed through Atrium’s working capital, as well as from a new banking credit facility. “The Multichem acquisition allows us to significantly increase our presence on
This acquisition was financed through Atrium’s working capital, as well as from a new banking credit facility. “The Multichem acquisition allows us to significantly increase our presence on
Tiazac XC is a novel, extended-release formulation of diltiazem hydrochloride that features a new diffusion technology (DiTech) delivery system designed for night-time administration, resulting in improved 24-hour blood
The antibody therapeutics are generated from two validated Millennium targets: a co-stimulatory molecule and a chemokine receptor. The co-stimulatory molecule is a CD28 homologue and has been implicated
The new program will focus on a specific drug target proposed by Merck, and Alnylam will proceed with preclinical development of an RNAi therapeutic for this target. The
Under the terms of the collaboration, Nektar will be responsible for formulation of the dry powder and development of the inhalation system, as well as clinical and commercial
An initial research collaboration agreement gave Schering exclusive marketing rights in Europe, while Novartis held corresponding rights for North America. Under the new agreement, Schering and Novartis will
ND7001 acts on a new target that has never been associated with depression or anxiety. It is the first representative of a new generation of psycho-active compounds potentially
Zelos is currently developing an injectable form of Ostabolin-C for the treatment of osteoporosis and has completed three phase I clinical trials. Parathyroid hormone (PTH) compounds are considered
In addition, Genzyme filed a motion for preliminary injunction to immediately seize and destroy all Gene-Activated glucocerebrosidase (GA-GCB) being used to treat patients in TKT’s ongoing clinical trial
Earlier in January, Ranbaxy announced that it had begun filing data for its range of anti-retrovirals (ARVs) with the FDA under its expedited review process for the US